Literature DB >> 18613418

Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma.

Susumu Takamatsu1, Norio Noguchi, Atsushi Kudoh, Noriaki Nakamura, Tohru Kawamura, Kenichi Teramoto, Tohru Igari, Shigeki Arii.   

Abstract

BACKGROUND/AIMS: We investigated a relationship between the risk factors for metabolic syndrome, such as obesity, diabetes mellitus, hypertension, and hyperlipidemia, and the pathogenesis and outcome of hepatocellular carcinoma (HCC).
METHODOLOGY: One hundred twenty four patients who underwent curative resections for HCC were classified into 3 groups: those patients who were positive for hepatitis B surface antigen (group B), those positive for antibody to hepatitis C virus (group C), and those negative for both of them (non-B non-C) (group NBNC). The preoperative laboratory data, risk factors for metabolic syndrome, history of alcohol abuse, and outcome after surgery were investigated. The presence of non-alcoholic steatohepatitis (NASH) was also evaluated.
RESULTS: The incidence of diabetes mellitus, hyperlipidemia, and alcohol abuse, and the serum level of triglyceride were significantly higher in group NBNC than in groups B or C. The risk factors for metabolic syndrome tended to lower the survival rates in group B and C, but not in group NBNC. Three of the 37 non-B non-C patients were associated with NASH.
CONCLUSIONS: It is suggested that the pathogenesis of non-B non-C HCC may be more closely associated with the risk factors for metabolic syndrome than that of hepatitis virus related HCC.

Entities:  

Mesh:

Year:  2008        PMID: 18613418

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  23 in total

1.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 2.  Environmental health in the biology century: Transitions from population to personalized prevention.

Authors:  John D Groopman
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-20

3.  Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.

Authors:  Valter Donadon; Massimiliano Balbi; Francesca Valent; Angelo Avogaro
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 4.  Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease.

Authors:  Onkar Bedi; Savera Aggarwal; Nirupma Trehanpati; Gayatri Ramakrishna; Pawan Krishan
Journal:  J Clin Exp Hepatol       Date:  2018-11-12

5.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Thomas A Abrams; Steven R Alberts; Daniel Anaya Saenz; Chandrakanth Are; Daniel B Brown; Daniel T Chang; Anne M Covey; William Hawkins; Renuka Iyer; Rojymon Jacob; Andrea Karachristos; R Kate Kelley; Robin Kim; Manisha Palta; James O Park; Vaibhav Sahai; Tracey Schefter; Carl Schmidt; Jason K Sicklick; Gagandeep Singh; Davendra Sohal; Stacey Stein; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Andrew X Zhu; Karin G Hoffmann; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

6.  Clinicopathological characteristics of hepatitis B surface antigen-negative and hepatitis C antibody-negative hepatocellular carcinoma.

Authors:  Hiroya Iida; Tsukasa Aihara; Shinichi Ikuta; Naoki Yamanaka
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

7.  Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma.

Authors:  Grace Guzman; Rohini Chennuri; Alexander Chan; Bryan Rea; Ada Quintana; Roshan Patel; Pei-Zhang Xu; Hui Xie; Nissim Hay
Journal:  Dig Dis Sci       Date:  2014-11-08       Impact factor: 3.199

8.  Low DMT1 Expression Associates With Increased Oxidative Phosphorylation and Early Recurrence in Hepatocellular Carcinoma.

Authors:  Toshifumi Hoki; Eriko Katsuta; Li Yan; Kazuaki Takabe; Fumito Ito
Journal:  J Surg Res       Date:  2019-02       Impact factor: 2.192

Review 9.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

10.  Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells.

Authors:  Dan Cao; Xinhua Song; Li Che; Xiaolei Li; Maria G Pilo; Gianpaolo Vidili; Alberto Porcu; Antonio Solinas; Antonio Cigliano; Giovanni M Pes; Silvia Ribback; Frank Dombrowski; Xin Chen; Lei Li; Diego F Calvisi
Journal:  Liver Int       Date:  2016-07-06       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.